Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
36.55B
Market cap36.55B
Price-Earnings ratio
105.80
Price-Earnings ratio105.80
Dividend yield
—
Dividend yield—
Average volume
1.00M
Average volume1.00M
High today
—
High today—
Low today
—
Low today—
Open price
$251.26
Open price$251.26
Volume
0.00
Volume0.00
52 Week high
$261.00
52 Week high$261.00
52 Week low
$160.36
52 Week low$160.36

Stock Snapshot

With a market cap of 36.55B, Biogen(BIIB) trades at $247.13. The stock has a price-to-earnings ratio of 105.80.

Biogen(BIIB) stock opened on 2026-11-20 at $251.26. The price climbed to — and dipped to —.

The Biogen(BIIB)'s current trading volume is 0, compared to an average daily volume of 1M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $261.00 and a 52-week low of $160.36.

In the last year, Biogen(BIIB) shares hit a 52-week high of $261.00 and a 52-week low of $160.36.

BIIB News

MarketWatch 16h
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch

...

Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Benzinga 2d
Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline

Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheim...

Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
Seeking Alpha 3d
Biogen releases new mid-stage data for early Alzheimer's asset diranersen

Phase 2, open-label extension data from Biogen's (BIIB) diranersen for early Alzheimer's disease showed that the asset led to a significant slowing of clinical...

Biogen releases new mid-stage data for early Alzheimer's asset diranersen

Analyst ratings

65%

of 37 ratings
Buy
64.9%
Hold
29.7%
Sell
5.4%

More BIIB News

TipRanks 3d
Biogen says diranersen demonstrates increasing clinical benefit at two years

Biogen (BIIB) announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide th...

The Motley Fool 3d
Biogen: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Biogen (BIIB -0.34%) announced that it's on track to deliver full-year top-line growth, driven b...

Biogen: 3 Key Takeaways for Long-Term Investors
Simply Wall St 6d
Biogen, Why Is Its Latest Update Drawing Attention?

Biogen (BIIB) drew fresh interest after two product updates. Eisai and Biogen launched the weekly at home LEQEMBI Pen in Japan for early Alzheimer’s disease, wh...

Biogen, Why Is Its Latest Update Drawing Attention?

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.